At the EGM the shareholders of Molecular Partners approved the election of William (Bill) Burns, former CEO of Roche Pharmaceuticals, and Patrick Amstutz, CEO of Molecular Partners, as new members of the Board of Directors with large majorities.
Monthly Archives: October 2017
Molecular Partners announced its Interim Management Statement for the period ending September 30, 2017.
The first patient was dosed in the phase 1 clinical study of Molecular Partners’ oncology asset MP0274, a proprietary DARPin® drug candidate for the treatment of HER2-positive cancer with a new mode of action compared to current standard of care antibodies.
Molecular Partners published the invitation to EGM on October 31, 2017.
The Board of Directors of Molecular Partners has nominated William (Bill) Burns, former CEO of Roche Pharmaceuticals, for election to the Board at an EGM on October 31, 2017, after which the Board of Directors plans to appoint him Vice-Chairman. At the EGM Patrick Amstutz, CEO of Molecular Partners, also stands for election to the Board.